Skip to content

New heat-stable ritonavir tablet approved in Europe

Merck will not seek vicriviroc licenses in treatment-experienced

New hepatitis C protease inhibitors achieve 80% ‘cure’ rate in patients with genotype 1 infection

FDA committee recommends approval of maraviroc for first-line treatment in US

Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression

Maturation inhibitor bevirimat is well tolerated and effective in predicted responders

GSK's second integrase inhibitor looks potent and well-tolerated in early study

Nutritional formula linked to reduced CD4 cell loss in untreated people